Publication: FiercePharma

First reported 14 hours ago - Updated 40 mins ago - 1 reports

Ex-Sanofi CEO Viehbacher in line for up to $7.8M cash payoff

Sanofi severance package a fraction of U.S. pharma's golden parachutesShareToolsFormer Sanofi CEO Chris ViehbacherWhen a CEO falls from grace, people want to know how soft the landing might be. For the now-former chief of Sanofi, Chris Viehbacher, there's ... [Published FiercePharma - 14 hours ago]
First reported 11 hours ago - Updated 4 hours ago - 1 reports

Copaxone, still growing, helps Teva pass Q3 estimates

Sales of Teva's ( $TEVA ) multiple sclerosis drug, Copaxone , are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales. That, ... [Published FiercePharma - 11 hours ago]
First reported 15 hours ago - Updated 9 hours ago - 1 reports

CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg

AstraZeneca CEO Pascal SoriotBernstein analyst Tim Anderson figures Sanofi ($SNY) would do well to look outside the company for its new CEO, like AstraZeneca ($AZN) did with its new-ish chief, Pascal Soriot. Well, Sanofi had a more literal view: The French ... [Published FiercePharma - 15 hours ago]
First reported 12 hours ago - Updated 11 hours ago - 1 reports

Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Deal-hungry Perrigo ($PRGO) is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company is said to be close to sealing the deal for Belgian OTC maker Omega Pharma, inching past big-name competitors like ... [Published FiercePharma - 12 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

New-drug sales boost plus OTC buyout yields $53B forecast for Bayer

Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, the company said Thursday as it raised its revenue and profit forecasts.The German ... [Published FiercePharma - 11 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Sales up 8% so far this year, despite some formulary hits, company saysShareToolsNovo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next year, ... [Published FiercePharma - 12 hours ago]
First reported Oct 29 2014 - Updated 17 hours ago - 1 reports

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

When Sanofi ( $SNY ) announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage--which the company ... [Published FiercePharma - Oct 29 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo?

What about that diabetes price war? When Sanofi ($SNY) announced that its franchise would suffer next year because of U.S. payer contracts, that was the natural follow-up question. If Sanofi had to boost its rebates to win coverage--which the company ... [Published FiercePharma - Oct 29 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Gilead misses the mark in Q3 due to Obamacare fee and dip in Sovaldi revenue

Gilead's Sovaldi--Courtesy of GileadGilead Sciences ($GILD) is charging full speed ahead in 2014, charting eye-popping sales for blockbuster Sovaldi and chalking up a key regulatory approval for its new hep C combo pill, Harvoni. But the company's third-quarter ... [Published FiercePharma - Oct 29 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 2 reports

A tale of 'two worlds' for Novartis respiratory launches in U.S. and EU

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get ... [Published FiercePharma - Oct 29 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Bayer, Merck KGaA spend big bucks for market share in China

Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies like diabetes. So how are Germany's leading pharmas, Bayer and Merck KGaA, carving ... [Published FiercePharma - Oct 29 2014]
Entities: Merck KGaA, China, Bayer AG
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Pfizer CEO: 'No reason' we can't do an inversion deal, Treasury rules or no

Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas. Despite the U.S. government's attempt to discourage tax inversions--like the one Pfizer ($PFE) would have achieved by buying AstraZeneca ($AZN)--Read ... [Published FiercePharma - Oct 29 2014]

Quotes

And according to CEO Marijn Dekkers, who has long said his goal is to top the world OTC market, more deals could be Bayer's short-term plan. "We are looking to expand our business in the future through both organic growth and acquisitions, he said on a conference call, as quoted by Reuters."
But don't jump to any conclusions, CSO Mads Krogsgaard Thomsen said during the earnings call. "Our confidence in 'DEVOTE' and the interim analysis is completely unabated and unchanged" he said. "It is just a change in strategy."
...they aren't offering significant incremental discounts," Fernandez said in a Wednesday investor note, adding that execs repeatedly said Novo has "little interest in pursuing exclusive contracts with payers in the U S "
...advantages, Deloitte China partner Mike Braun told the WSJ, and Merck's biopharma chief exec, Belén Garijo, told the paper its Nantong plant would "allow us to grow faster by producing all of our major brands for China."

More Content

All (198) | News (198) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New-drug sales boost plus OTC buyout yields $53... [Published FiercePharma - 11 hours ago]
Copaxone, still growing, helps Teva pass Q3 est... [Published FiercePharma - 11 hours ago]
Deal-hungry Perrigo elbows aside competitors fo... [Published FiercePharma - 12 hours ago]
Novo Nordisk quells diabetes pricing fears with... [Published FiercePharma - 12 hours ago]
Ex-Sanofi CEO Viehbacher in line for up to $7.8... [Published FiercePharma - 14 hours ago]
CEO-hunting Sanofi tried to tempt AstraZeneca's... [Published FiercePharma - 15 hours ago]
Who's the diabetes price-cutting culprit: Lilly... [Published FiercePharma - Oct 29 2014]
Gilead misses the mark in Q3 due to Obamacare f... [Published FiercePharma - Oct 29 2014]
Bayer, Merck KGaA spend big bucks for market sh... [Published FiercePharma - Oct 29 2014]
A tale of 'two worlds' for Novartis respiratory... [Published FiercePharma - Oct 29 2014]
Diabetes pricing war? Sanofi, Lilly and Novo ea... [Published FiercePharma - Oct 29 2014]
Pfizer CEO: 'No reason' we can't do an inversio... [Published FiercePharma - Oct 29 2014]
Like Novartis before it, AstraZeneca benefits b... [Published FiercePharma - Oct 29 2014]
For Novartis' respiratory ambitions, it's a tal... [Published FiercePharma - Oct 29 2014]
'See-through' sensors for the brain are transpa... [Published FiercePharma - Oct 29 2014]
Nanosphere reels in $18.4M in stock sale [Published FiercePharma - Oct 29 2014]
Sanofi board: We've dismissed CEO Chris Viehbacher [Published FiercePharma - Oct 29 2014]
Orphan drug pricing for non-orphan meds? Expres... [Published FiercePharma - Oct 28 2014]
Is $200 a share from Valeant enough after Aller... [Published FiercePharma - Oct 28 2014]
Novartis gets 4% sales lift as 'growth products... [Published FiercePharma - Oct 28 2014]
Pfizer beats the Street's Q3 expectations but s... [Published FiercePharma - Oct 28 2014]
Orphan drug prices on non-orphan meds? Gilead, ... [Published FiercePharma - Oct 28 2014]
Big trouble in Sanofi's diabetes biz sends shar... [Published FiercePharma - Oct 28 2014]
Big relief for Lilly, Boehringer as judge slash... [Published FiercePharma - Oct 28 2014]
FDA grants bioMérieux emergency authorization f... [Published FiercePharma - Oct 27 2014]
Will buyers bite for Unipharm amid Russian M&A ... [Published FiercePharma - Oct 27 2014]
Is Viehbacher's job in danger? Some Sanofi dire... [Published FiercePharma - Oct 27 2014]
Novartis unloads last piece of vaccines puzzle ... [Published FiercePharma - Oct 27 2014]
Merck bogged down by slumping sales, but cuts d... [Published FiercePharma - Oct 27 2014]
U.S. Attorney asks Novo Nordisk about plant in ... [Published FiercePharma - Oct 27 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.